Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Lipocine Inc (LPCN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Lipocine's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.5500 +0.1100    +2.48%
25/04 - Closed. Currency in USD ( Disclaimer )
After Hours
4.7100
+0.1600
+3.5165%
16:57:06 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 7,965
  • Bid/Ask: 4.0300 / 4.7500
  • Day's Range: 4.4100 - 4.6047
Lipocine 4.5500 +0.1100 +2.48%

Lipocine Inc Company Profile

 
Get an in-depth profile of Lipocine Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

17

Equity Type

ORD

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Contact Information

Address 675 Arapeen Drive Suite 202
Salt Lake City, 84108
United States
Phone 801 994 7383
Fax 801 994 7388

Top Executives

Name Age Since Title
Jill M. Jene 49 2022 Independent Director
Mahesh V. Patel 65 1997 Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Rex P. Hjelm - - Member of Scientific Advisory Board
William N. Charman 63 - Member of Scientific Advisory Board
Richard Dana Ono 70 2014 Independent Director
Alan F. Hofmann - - Member of Scientific Advisory Board
George Zografi - - Member of Scientific Advisory Board
Leslie Z. Benet 85 - Member of Scientific Advisory Board
Tsuneji Nagai - - Member of Scientific Advisory Board
John W. Higuchi 55 2003 Director
Bradley D. Anderson - - Member of Scientific Advisory Board
Ronald T. Borchardt - - Member of Scientific Advisory Board
Norman Ho - - Member of Scientific Advisory Board
Jeffrey Arvin Fink 65 2014 Independent Director
Spyridon Papapetropoulos 51 2022 Lead Independent Director & Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LPCN Comments

Write your thoughts about Lipocine Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Costas Socolis
Costas Socolis Apr 17, 2024 4:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Back to 3.00 $ for one more time
Mario Fe
Mario Fe Apr 17, 2024 4:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Keep dreaming...
Costas Socolis
Costas Socolis Apr 17, 2024 4:56AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
told you but you don't listen
Costas Socolis
Costas Socolis Mar 13, 2024 7:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dead horse.
Mario Fe
Mario Fe Mar 13, 2024 7:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why? Its up more than 50% in two months!! It should go to 15/20$ by the end of the year with the new sales!!
Costas Socolis
Costas Socolis Mar 13, 2024 7:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
keep dreaming
Mario Fe
Mario Fe Mar 13, 2024 7:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Just wait for several FDA aprovals... One thing is sure, their not dead!
Mario Fe
Mario Fe May 11, 2023 11:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1$ by the end of the year
Costas Socolis
Costas Socolis Dec 07, 2022 5:49AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Ladenburg Thalmann analyst raised the price target on Lipocine Inc (LPCN) to $4.00 (from $2.50) while maintaining a Buy rating
Israel Orozco
Israel Orozco Nov 11, 2022 5:13PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Hi!!
anthony jones
anthony jones Jul 13, 2021 11:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ALYI
anthony jones
anthony jones Jun 23, 2021 12:23PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀
Costas Socolis
Costas Socolis Jun 03, 2021 2:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LPCN IA going down...
Hussein Huda
Hussein Huda Apr 07, 2021 5:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock made me crazy
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email